Home Molecular Testing Methods Sanger Sequencing Test: Single-Gene Variants and Results

Sanger Sequencing Test: Single-Gene Variants and Results

By
Vita Library
-
4
Sanger sequencing reads targeted gene regions to find or confirm small DNA variants. Understand chromatograms, result categories, limitations, and follow-up testing.

Sanger sequencing is a focused DNA test that reads the order of bases in a selected gene region. It is often used when a clinician suspects a disorder linked to one gene, when a known family variant needs confirmation, or when another sequencing method produces a result that requires a second look. The method generates an easy-to-review signal across a relatively short stretch of DNA, making it highly accurate for many single-base substitutions and small insertions or deletions.

Its focus is also its main limitation. Sanger sequencing usually examines only the exons or specific regions requested by the laboratory. It generally does not provide a broad search across many genes and may miss large deletions, duplications, repeat expansions, deep intronic variants, low-level mosaicism, or changes hidden by a highly similar pseudogene. A result is meaningful only when the tested region and method match the suspected condition.

  • Sanger sequencing reads one targeted DNA region at a time.
  • It is commonly used for single-gene diagnosis, family testing, and confirmation of selected variants.
  • A chromatogram shows the sequence signal and helps reviewers identify mixed or altered bases.
  • Strong performance for small variants does not mean every type of genetic change is detectable.
  • Negative results must be interpreted according to the exact exons, boundaries, and variant types tested.

Table of Contents

What Sanger Sequencing Is

Sanger sequencing determines the order of the four DNA bases—adenine, cytosine, guanine, and thymine—within an amplified DNA segment. The method is also called chain-termination sequencing or capillary sequencing. It was developed before modern high-throughput sequencing and remains widely used because it produces a clear, directly inspectable read for a defined target.

The test begins with a question such as: Does this person have a disease-causing variant in a particular exon? Did a child inherit the variant already identified in a parent? Is an apparent change from a broader panel truly present in the original sample? The laboratory designs short primers around that region, makes many copies with PCR, and sequences the product.

Sanger sequencing differs from a broad next-generation sequencing test. NGS reads millions of fragments in parallel and can examine many genes at once. Sanger usually processes one fragment per reaction, although multiple reactions can be run across a gene. This makes it inefficient for very large genes or disorders with many possible genetic causes, but efficient when the target is narrow and well defined.

A typical high-quality Sanger read covers several hundred bases. Laboratories often sequence both the forward and reverse directions so that each base is supported from opposite strands. The usable length varies with DNA quality, primer performance, sequence complexity, and the instrument. Bases near the beginning or end of a read may be lower quality and can require a redesigned reaction.

The output is a chromatogram, also called an electropherogram. It displays colored peaks corresponding to DNA bases. A person with two identical bases at a position generally shows one clean peak. A person with two different bases at the same position may show two overlapping peaks of similar height. Insertions and deletions can create a mixed pattern beginning at the altered site because the two copies of the chromosome are no longer aligned in the same way.

Sanger sequencing is an analytic method, not a diagnosis by itself. The laboratory must compare the observed sequence with an accepted reference transcript, describe the variant using standardized nomenclature, and classify its clinical significance. The result then has to be matched with inheritance, symptoms, and other evidence.

When the Test Is Used

Sanger sequencing is most useful when the gene or exact variant is already strongly suspected. The clinical indication determines whether the laboratory sequences one site, several exons, or an entire coding region.

Single-gene diagnostic testing

A clinician may order Sanger sequencing when the patient’s findings closely match a disorder caused mainly by variants in one gene. Examples include certain familial conditions with a distinctive clinical pattern, some enzyme deficiencies, and disorders for which a small number of gene regions account for many cases. The laboratory may sequence all coding exons and nearby splice boundaries or only selected hotspots.

Single-gene testing can be more focused and easier to interpret than a large panel. It may also provide complete coverage of regions that are difficult for some NGS assays. However, it is less efficient when several genes can cause nearly identical symptoms. In that setting, a multigene panel, exome, or genome test may have a higher chance of finding the cause without sequentially testing genes one by one.

Testing a known family variant

After a pathogenic or likely pathogenic variant is identified in one family member, relatives may need testing for that exact change. Sanger sequencing is well suited to this targeted question. Only the small region containing the familial variant needs to be amplified and read. This is often called targeted variant testing rather than full-gene sequencing.

Testing relatives can clarify who has inherited a condition or an increased disease risk. It may also support reproductive planning or determine whether a parent carries a variant found in a child. The laboratory should receive a copy of the original report, because gene names, transcript versions, and DNA coordinates must be matched accurately.

Segregation analysis

Segregation analysis examines whether a variant tracks with disease in a family. Finding the same variant in several affected relatives and not in unaffected relatives may strengthen evidence for pathogenicity, depending on family size and disease penetrance. Conversely, finding a suspected highly penetrant variant in healthy older relatives can argue against a causal role.

Sanger sequencing is frequently used for this purpose because it can test one candidate variant in many relatives. Family results are not interpreted mechanically. Reduced penetrance, variable expression, de novo occurrence, mosaicism, nonpaternity, and phenocopies can complicate the pattern.

Confirmation of results from other methods

Sanger sequencing has historically been used to confirm variants detected by NGS. Current laboratories may instead validate NGS quality thresholds and report high-confidence variants without routine Sanger confirmation. Confirmation remains useful for low-quality calls, difficult sequence contexts, some insertions or deletions, and cases in which an independent method materially reduces the risk of error.

Sanger is not always the best confirmation method. A copy-number change may require multiplex ligation-dependent probe amplification, array analysis, or quantitative PCR. A repeat expansion may require repeat-primed PCR or Southern blot. Low-level mosaicism may require deep amplicon sequencing or digital PCR. The confirming test should measure the same type of alteration with adequate sensitivity.

Prenatal, preimplantation, and tumor applications

Sanger sequencing can test a known familial variant in prenatal specimens or support a single-gene preimplantation testing strategy. These applications require strict identity controls and specialized interpretation because maternal cell contamination, allele dropout, and limited DNA can affect results.

In tumors, Sanger can identify a high-frequency somatic variant in a well-defined hotspot, but it is usually less sensitive than modern targeted NGS for low variant fractions. The laboratory must account for tumor percentage and normal-cell dilution. A negative tumor Sanger result may not exclude a mutation present in only a small subpopulation of cells.

From Sample to Chromatogram

Most inherited-disease Sanger tests use DNA from blood, saliva, or a cheek swab. Prenatal tests may use chorionic villus or amniotic fluid samples. Tumor testing uses tissue, cytology material, blood, or another validated specimen. The laboratory extracts DNA and checks whether its amount and quality are sufficient.

The workflow usually includes these steps:

  1. Target selection: The laboratory identifies the exon, splice boundary, or variant site to be tested and selects the correct reference transcript.
  2. Primer design: Two short DNA primers are designed to bind on either side of the target. Primers must avoid common variants and highly similar regions when possible.
  3. PCR amplification: The target is copied many times. A clean, specific product is important because mixed amplification produces an unreadable sequence.
  4. Product cleanup: Excess primers, nucleotides, and unwanted reaction components are removed.
  5. Sequencing reaction: The amplified DNA is copied using normal nucleotides plus fluorescently labeled chain-terminating nucleotides. Each terminated fragment ends at a known base.
  6. Capillary electrophoresis: Fragments travel through a thin capillary. Smaller fragments pass first, and a detector records the fluorescent label at each position.
  7. Sequence analysis: Software converts the signal into a base sequence and assigns quality values. A trained reviewer inspects the chromatogram, especially around any candidate variant.
  8. Clinical interpretation: The laboratory confirms nomenclature, evaluates evidence, and issues the report.

PCR is central to the method. Problems at this stage can affect the entire result. If one chromosome amplifies better than the other, a heterozygous variant may appear weaker or may be missed. This is called allelic imbalance or, in an extreme case, allele dropout. A common variant under a primer can prevent that chromosome from amplifying. Good laboratories validate primer sites and may use an alternative primer set when the pattern is suspicious.

The chromatogram is assessed for peak shape, baseline noise, spacing, signal intensity, and agreement between directions. A clean sequence has narrow, evenly spaced peaks. Broad peaks, overlapping signals across the entire read, or rapidly falling signal can indicate poor template, nonspecific PCR, contamination, or an insertion/deletion.

When an insertion or deletion is present in one gene copy, the two alleles become offset after the variant. The chromatogram may appear clean before the change and mixed afterward. Specialized software can sometimes resolve the two sequences, but the laboratory may redesign primers, clone the product, or use another method if the exact change remains uncertain.

Variants Sanger Sequencing Can Detect

Sanger sequencing performs best for small sequence variants within the amplified region. Its reportable range should be stated by the laboratory.

Single-nucleotide variants

A single-nucleotide variant changes one DNA base. In a heterozygous germline result, the chromatogram generally shows two peaks at one position. In a homozygous or hemizygous result, one altered peak replaces the reference base. Sanger is highly accurate for these changes when the sequence is clean and both alleles amplify equally.

Small insertions and deletions

Sanger can detect many small insertions and deletions, often called indels. Exact performance depends on size and sequence context. A heterozygous indel causes overlapping peaks downstream, while a homozygous indel may be easier to read directly. Larger indels may amplify poorly or create preferential amplification of the shorter allele.

Variants near splice boundaries

Full-gene Sanger assays commonly include a limited number of intronic bases beside each exon. Variants in these regions may alter RNA splicing. The exact boundary covered varies, so a negative report should not be assumed to exclude deep intronic variants. RNA studies may be needed to determine whether an uncertain splice-region change affects the transcript.

Known mosaic variants at sufficient levels

Sanger can sometimes show mosaicism when the altered DNA represents a substantial proportion of the specimen. The abnormal peak may be visibly smaller than the reference peak. Detection is not reliable at low variant fractions, and the practical threshold varies with base combination, local noise, reviewer judgment, and assay validation. Suspected low-level mosaicism should be evaluated with a more sensitive quantitative method.

What standard Sanger sequencing usually does not detect

Unless specifically adapted, Sanger sequencing is not designed to find:

  • whole-exon or whole-gene deletions and duplications;
  • balanced rearrangements or distant breakpoints;
  • large repeat expansions;
  • variants outside the amplified exons and boundaries;
  • low-level mosaic variants;
  • epigenetic changes such as abnormal methylation;
  • mitochondrial heteroplasmy below the assay threshold;
  • changes in genes not selected for testing.

A large deletion can occasionally be inferred if an expected PCR product is absent, but PCR failure has many causes. In a person with two gene copies, the normal allele may amplify and conceal a deletion of the other allele. Dedicated deletion/duplication analysis is therefore needed when that variant type is clinically relevant.

Highly homologous genes and pseudogenes create another challenge. Primers may amplify both the true gene and a similar inactive copy, producing mixed sequence or assigning a pseudogene variant to the wrong location. Specialized long-range PCR, gene-specific primers, or alternative technologies may be required. This issue is important in genes such as PMS2, CYP21A2, SMN1/SMN2, and others with closely related sequences, although the optimal method differs by gene.

How Results Are Interpreted

A Sanger report should state what was tested, which reference transcript was used, what variants were found, and how they were classified. For diagnostic testing, the main result categories are positive, carrier, uncertain, negative, or inconclusive.

Pathogenic or likely pathogenic variant

A pathogenic or likely pathogenic variant has enough evidence to support a disease association. The report usually lists the gene, transcript, cDNA change, predicted protein change, zygosity, and classification. It may explain whether the finding matches an autosomal dominant, autosomal recessive, X-linked, or mitochondrial inheritance pattern.

One variant may be sufficient for a dominant condition. For a recessive condition, two disease-causing variants usually must be present on opposite gene copies. Sanger sequencing can find both variants but may not determine whether they are in cis or trans. Testing parents can establish phase in many families.

A molecular result does not guarantee a particular symptom or age of onset. Penetrance and severity can vary. The finding should be interpreted with the patient’s phenotype and family history.

Carrier result

A person with one pathogenic variant for an autosomal recessive condition is usually described as a carrier. Carriers often do not have the full disorder, although some genes have recognized carrier manifestations. Partner testing and reproductive counseling may be appropriate.

In an X-linked condition, terminology and risk depend on sex chromosomes, gene, and disease mechanism. A heterozygous person may be asymptomatic or may have clinical features because of X-inactivation or other factors.

Variant of uncertain significance

A variant of uncertain significance, or VUS, does not have enough evidence to be called disease-causing or benign. It should not generally be used alone to make major medical decisions or to test healthy relatives for predictive purposes. Segregation studies may sometimes provide useful evidence, but not every family test resolves uncertainty.

Benign or likely benign variant

Benign and likely benign variants are not considered the cause of the tested disorder. Laboratories often omit common benign findings from the main report unless they are relevant to assay interpretation or requested under policy.

Negative result

A negative result means no reportable variant was found in the regions and variant classes analyzed. It does not eliminate the possibility of a genetic condition. The cause may be in another gene, an untested exon, a regulatory region, a repeat, a copy-number change, or a tissue-limited mosaic variant. It may also reflect a nongenetic condition.

The value of a negative result depends on pretest probability. When the clinical picture is highly specific and Sanger covered nearly all known disease-causing regions, the result can substantially reduce the likelihood of that diagnosis. When many genes can produce the same phenotype, a negative single-gene test may only indicate that broader testing is needed.

Inconclusive result

An inconclusive report can result from poor DNA quality, failed amplification, a complex chromatogram, or inability to distinguish a gene from its pseudogene. The laboratory may request a new specimen, test an alternative region, or recommend another technology.

Technical Limits and Sources of Error

Sanger sequencing is often described as a gold-standard method, but that phrase should not be interpreted as error-free. Accuracy depends on specimen identity, primer specificity, sequence quality, analytic review, and correct clinical interpretation.

Potential technical problems include sample swaps, contamination, PCR failure, allele dropout, poor-quality sequence, and reference-transcript mismatch. Laboratories use barcodes, controls, bidirectional reads, independent review, and repeat testing to reduce these risks. Confirmation from a second specimen may be appropriate when a result has major consequences and sample identity is uncertain.

Mosaicism deserves special attention. A person can carry a variant in only part of the body or in only a fraction of cells. Blood may be negative even when the variant is present in skin, brain, tumor, or reproductive cells. Conventional Sanger signal is not reliably quantitative at low levels. Deep sequencing or digital PCR can detect much smaller variant fractions and should be considered when mosaicism would change recurrence risk or treatment.

Tumor samples add complications. Formalin can damage DNA and create artifacts. Low tumor content dilutes the abnormal allele, while copy-number changes can distort peak ratios. The laboratory’s limit of detection should be appropriate for the estimated tumor percentage. A test designed for inherited heterozygous variants may not be validated for low-frequency somatic changes.

Another limitation is ascertainment. Sanger only sees the region between the primers. Even complete coding-region testing may leave untranslated regions, promoters, enhancers, deep introns, and structural variants unexamined. The test requisition and report should define coverage rather than relying on the phrase “gene sequencing.”

Interpretation can also change. A variant classified as uncertain today may be reclassified as benign or pathogenic as population databases, functional studies, and clinical observations grow. Patients can ask whether the laboratory accepts requests for reinterpretation and whether amended reports are issued.

Preparation, Timing, and Next Steps

Most blood or saliva Sanger tests require no fasting. The patient should provide accurate identity information, relevant clinical features, and family history. For targeted family testing, a copy of the relative’s laboratory report is essential; a handwritten description of the variant may omit the transcript or nomenclature needed to design the correct assay.

Turnaround time is often shorter for a known variant than for full-gene sequencing. A targeted test may take several days to a few weeks, while complete sequencing and interpretation can take longer. Prenatal and urgent tests may follow accelerated workflows. Timing depends on laboratory capacity, specimen quality, and whether repeat reactions are necessary.

After a positive result, next steps may include genetic counseling, testing relatives, condition-specific surveillance, or referral to a specialist. In recessive disease, parental testing can determine whether two variants are on opposite chromosomes. In a child with an apparently de novo variant, testing parents can refine recurrence risk, although low-level germline mosaicism cannot always be excluded.

After a VUS, management should continue to rely on clinical findings and family history rather than treating the variant as a confirmed diagnosis. The care team may seek additional family samples, functional evidence, or periodic reinterpretation.

After a negative result, the next test should address what Sanger did not cover. Options may include deletion/duplication analysis, a multigene panel, exome or genome sequencing, repeat-expansion testing, methylation analysis, RNA studies, or testing a more appropriate tissue. Repeating the same sequencing without a clear reason is less useful than selecting a method matched to the remaining possibilities.

Before acting on any result, confirm that the report pertains to the correct person, gene, and clinical question. Review the tested regions and limitations, not only the conclusion. A genetic counselor or genetics clinician can translate the laboratory finding into personal and family implications and help decide whether additional testing is warranted.

References

Disclaimer

This article provides general educational information and is not a substitute for individualized medical or genetic advice. Test coverage, sensitivity, nomenclature, and reporting policies differ among laboratories. A qualified clinician or genetic counselor should interpret results in the context of symptoms, family history, and the complete laboratory report.

RELATED ARTICLESMORE FROM AUTHOR